CYLD and gastric cancer: A study reported that RP1-228H13.5, referred in that study as CRAL, is downregulated in cisplatin-resistance in gastric cancer (GC) cells and contributes to cisplatin-resistant in GC cells via impairing cisplatin-induced DNA damage as well as cell apoptosis through the miR-505/CYLD/AKT axis54.